Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regadenoson in Marginal Donor Lung Rehabilitation
NCT04521569Phase 1Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- Jun 2020
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of regadenoson in ischemia-reperfusion injury (IRI) (2 arms), sponsored by University of Maryland, Baltimore. Primary endpoint: Lung Rehabilitation at 30 days. Started Jun 2020; status: completed.
02
Drugs
regadenoson
03
Conditions
ischemia-reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT04521569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04521569.